Which statement about CPPD management is true?

Which statement about CPPD management is true?

• A. Urate-lowering therapy is routinely used
• B. NSAIDs/colchicine/steroids are contraindicated
• C. Treat underlying metabolic conditions
• D. Purine-rich diets are recommended

Answer: (C)

CPPD management centers on addressing any underlying metabolic abnormalities while also controlling acute symptoms. Calcium pyrophosphate deposition disease (pseudogout) is often linked with conditions such as hyperparathyroidism, hemochromatosis, hypomagnesemia, and hypothyroidism. Treating these metabolic issues can reduce crystal deposition and lower the risk of future flares. For an acute CPPD flare, standard treatments include NSAIDs, colchicine, or corticosteroids, which are effective and not contraindicated for CPPD. Urate-lowering therapy is aimed at gout by reducing uric acid levels and does not target calcium pyrophosphate deposition, so it’s not routinely used for CPPD. Diets high in purines are not a proven strategy for CPPD and aren’t a standard recommendation, whereas the link between purine intake and CPPD is weak. So, addressing underlying metabolic conditions best reflects how CPPD is managed in practice.

CPPD management centers on addressing any underlying metabolic abnormalities while also controlling acute symptoms. Calcium pyrophosphate deposition disease (pseudogout) is often linked with conditions such as hyperparathyroidism, hemochromatosis, hypomagnesemia, and hypothyroidism. Treating these metabolic issues can reduce crystal deposition and lower the risk of future flares.

For an acute CPPD flare, standard treatments include NSAIDs, colchicine, or corticosteroids, which are effective and not contraindicated for CPPD. Urate-lowering therapy is aimed at gout by reducing uric acid levels and does not target calcium pyrophosphate deposition, so it’s not routinely used for CPPD. Diets high in purines are not a proven strategy for CPPD and aren’t a standard recommendation, whereas the link between purine intake and CPPD is weak.

So, addressing underlying metabolic conditions best reflects how CPPD is managed in practice.